BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1757612)

  • 1. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies.
    Bernhard J; Whitmore C; Guzzo C; Kantor I; Kalb RE; Ellis C; Urbach F; Schwartzel EH; Gibson JR
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1170-4. PubMed ID: 1757612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis.
    Katz HI; Gross E; Buxman M; Prawer SE; Schwartzel EH; Gibson JR
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1175-8. PubMed ID: 1757613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses.
    Guzzo CA; Weiss JS; Mogavero HS; Ellis CN; Zaias N; Lowe NJ; Kerdel FA; Milbauer JJ; Bernhard JD; Whitmore C
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1179-83. PubMed ID: 1757614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis.
    Goldberg B; Hartdegen R; Presbury D; Smith EH; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1145-8. PubMed ID: 1757605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis.
    Mensing H; Korsukewitz G; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1149-52. PubMed ID: 1757606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis.
    Blum G; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1153-6. PubMed ID: 1757607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis.
    Bhatia N; Stein Gold L; Kircik LH; Schreiber R
    J Drugs Dermatol; 2019 Aug; 18(8):790-796. PubMed ID: 31424709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis.
    Herz G; Blum G; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1166-9. PubMed ID: 1757611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
    Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
    J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus.
    Brunner N; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1160-3. PubMed ID: 1757609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
    Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
    Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
    J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
    Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
    J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
    [No Abstract]   [Full Text] [Related]  

  • 15. Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses.
    Kantor I; Cook PR; Cullen SI; Willis I; Gibson JR; Stanfield JW
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1184-6. PubMed ID: 1757615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
    Lebwohl M; Yoles A; Lombardi K; Lou W
    J Am Acad Dermatol; 1998 Sep; 39(3):447-50. PubMed ID: 9738781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
    Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
    J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus.
    Datz B; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1157-60. PubMed ID: 1757608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D and topical therapy.
    Lebwohl M
    Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
    Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
    J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.